Metastatic Urothelial Cancer

DrugDrug NameDrug Description
DB13007Enfortumab vedotinAn antibody-drug conjugate comprised of a fully human monoclonal antibody and microtubule-disrupting chemotherapeutic agent used in the treatment of advanced or metastatic urothelial cancer.
DrugDrug NamePhaseStatusCount
DB13007Enfortumab vedotin1Completed1
DB09037Pembrolizumab1Completed1
DB11945Avelumab2Recruiting1
DB00958Carboplatin2Recruiting2
DB00441Gemcitabine2Recruiting2
DB09035Nivolumab2Recruiting1
DB09074Olaparib2Recruiting1
DB00526Oxaliplatin2Recruiting1
DB01229Paclitaxel2Recruiting1
DB00958Carboplatin2 / 3Completed1
DB00515Cisplatin2 / 3Completed1
DB00441Gemcitabine2 / 3Completed1
DB00958Carboplatin3Recruiting1
DB00515Cisplatin3Recruiting1
DB11714Durvalumab3Recruiting1
DB11717Epacadostat3Active Not Recruiting1
DB00441Gemcitabine3Recruiting1
DB09037Pembrolizumab3Active Not Recruiting1
DB11771Tremelimumab3Recruiting1